Tag:
TroVax
Latest Headlines
Latest Headlines
Oxford BioMedica unveils promising data for TroVax
Oxford BioMedica had some promising data to report at a medical conference in Berlin, but investors may not have gotten the news. Oxford's stock initially dropped 18 percent this morning after the
FDA clears a path for TroVax trials, partnership
The FDA has given Oxford BioMedica a clear path to test its late-stage therapeutic vaccine TroVax for a variety of cancers, and the company has enthusiastically responded with plans to advance
Oxford BioMedica finds silver lining in Sanofi purge
Sanofi's pruning shears clipped off the once-promising Trovax, a therapeutic cancer vaccine that it had licensed from Oxford BioMedica. Now the UK developer says that Sanofi is handing the vaccine
Oxford shares surge on FDA trial talks
Shares of Oxford BioMedica jumped on the news that it's been conducting positive talks with the FDA on advancing clinical research on the renal cancer drug
GeneThera nixes takeover of troubled Oxford BioMedica
Troubled Oxford BioMedica has been roiled by several twists and turns in the last few days. Last week, newly named CEO Mike McDonald departed after only a month in the top job. That sent company
GeneThera bids for Oxford BioMedica
Oxford BioMedica's stock got a major boost today on news that U.S.-based GeneThera made a takeover bid for the company. However, Oxford quickly rejected the offer, saying that GeneThera was not a
Oxford BioMedica shares in meltdown on TroVax failure
Oxford BioMedica says that a late-stage trial of its lead drug therapy TroVax-a vaccine being studied for renal cancer-failed to hit its main objective. An advisory group said too many deaths in the
Is Sanofi preparing a bid for Oxford BioMedica?
Investors have focused their attention on Oxford BioMedica, a struggling UK developer that is the
